DUBLIN--(BUSINESS WIRE)--Aug 28, 2018--The "Acromegaly - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018" drug pipelines has been added to ResearchAndMarkets.com's offering.

Acromegaly - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2018' report provides comprehensive insights about marketed and Phase III products for Acromegaly.

The report includes information of marketed products including their product description, patent details, forecasted sales till 2020 & API manufacturer details by country. Coverage of API manufacturers for Acromegaly marketed products spanning across United States, Europe, China and India. The manufacturers' details include manufacturers' name along with their location.

This report provides a comprehensive understanding of the emerging Phase III therapies for Acromegaly which can turn out to be future prospective competitors for the marketed products. It will also put light on the current market trends. Their forecasted global sales are also provided till 2020.

Key Topics Covered:

1. Report Introduction

2. Acromegaly: Overview

3. Comparative Analysis of Marketed and Emerging Products

4. Marketed Therapies

5. Emerging Therapies (Phase III)

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7bvfbq/acromegaly?w=4.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180828005815/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD: EUROPE ASIA PACIFIC NORTH AMERICA SOUTH AMERICA AFRICA MIDDLE EAST

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL PROFESSIONAL SERVICES OTHER PROFESSIONAL SERVICES RESEARCH SCIENCE

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/28/2018 04:11 PM/DISC: 08/28/2018 04:11 PM

http://www.businesswire.com/news/home/20180828005815/en